Biopartnering Seminar Series - Defining and Demonstrating the Value of New Health Technologies

Tuesday, April 4, 2017 - 6:30pm

Defining and Demonstrating the Value of New Health Technologies - Ferg Mills, Director of Strategic Consulting, Innomar Consulting

The presentation will briefly describe the key features of the reimbursement of health technologies in Canada, covering the roles of clinical and economic evidence, and addressing the evidence requirements of payers and other stakeholders. Students can expect to enhance their understanding of the theoretical and practical considerations of launching new health technologies in the Canadian marketplace.

Ferg Mills is a Director of Strategic Consulting at Innomar Consulting, where he leads a team of health economists and outcomes researchers. As well as overseeing all aspects of reimbursement strategy and submission dossier development, Ferg and his team conduct data analytics and compose strategic publications for the products managed through patient support programs operated by Innomar. He is an expert in decision analytic modeling, and holds a BA in Economics from the University of Toronto and an MSc. in Health Technology Assessment from the University of York in the UK. Ferg is also the vice-president of the Canadian Association for Healthcare Reimbursement.